PL2152250T3 - Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku - Google Patents

Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku

Info

Publication number
PL2152250T3
PL2152250T3 PL07728851T PL07728851T PL2152250T3 PL 2152250 T3 PL2152250 T3 PL 2152250T3 PL 07728851 T PL07728851 T PL 07728851T PL 07728851 T PL07728851 T PL 07728851T PL 2152250 T3 PL2152250 T3 PL 2152250T3
Authority
PL
Poland
Prior art keywords
dosage forms
solid dosage
drug release
enteric coating
accelerated drug
Prior art date
Application number
PL07728851T
Other languages
English (en)
Inventor
Fang Liu
Abdul W Basit
Rosario Lizio
Hans-Ulrich Petereit
Christian Meier
Michael Damm
Original Assignee
Evonik Röhm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Röhm Gmbh filed Critical Evonik Röhm Gmbh
Publication of PL2152250T3 publication Critical patent/PL2152250T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
PL07728851T 2007-05-07 2007-05-07 Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku PL2152250T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2007/054398 WO2008135090A1 (en) 2007-05-07 2007-05-07 Solid dosage forms comprising an enteric coating with accelerated drug release
EP07728851.2A EP2152250B1 (en) 2007-05-07 2007-05-07 Solid dosage forms comprising an enteric coating with accelerated drug release

Publications (1)

Publication Number Publication Date
PL2152250T3 true PL2152250T3 (pl) 2020-06-15

Family

ID=39410284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07728851T PL2152250T3 (pl) 2007-05-07 2007-05-07 Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku

Country Status (19)

Country Link
US (2) US9597293B2 (pl)
EP (1) EP2152250B1 (pl)
JP (1) JP5167345B2 (pl)
KR (1) KR101443943B1 (pl)
CN (1) CN101663027B (pl)
AU (1) AU2007352872B2 (pl)
BR (1) BRPI0721654B8 (pl)
CA (1) CA2687130C (pl)
CY (1) CY1122582T1 (pl)
DK (1) DK2152250T3 (pl)
ES (1) ES2759626T3 (pl)
HU (1) HUE046488T2 (pl)
IL (1) IL201557A (pl)
LT (1) LT2152250T (pl)
MX (1) MX2009012030A (pl)
PL (1) PL2152250T3 (pl)
PT (1) PT2152250T (pl)
SI (1) SI2152250T1 (pl)
WO (1) WO2008135090A1 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
KR101315904B1 (ko) 2005-02-24 2013-10-08 디퓨젼 파마슈티컬즈 엘엘씨 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도
WO2008136900A1 (en) 2007-04-13 2008-11-13 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US9237760B2 (en) 2008-01-10 2016-01-19 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
NZ588407A (en) 2008-03-11 2012-07-27 Takeda Pharmaceutical Orally-disintegrating solid preparation
CN108464976A (zh) 2009-06-22 2018-08-31 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
EP3187171A1 (en) * 2012-04-30 2017-07-05 Tillotts Pharma AG A delayed release drug formulation
US20130295170A1 (en) * 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
CN104519876A (zh) 2012-08-27 2015-04-15 赢创工业集团股份有限公司 具有持续释放特征的和具有对乙醇影响的抗性的药物或保健品组合物
WO2014074749A1 (en) * 2012-11-07 2014-05-15 NaZura BioHealth, Inc. Gras enteric coating formulations and methods of making and using same
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US20150374632A1 (en) * 2013-02-22 2015-12-31 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
BR112016004863B1 (pt) 2013-10-29 2022-09-20 Tillotts Pharma Ag Formulação de droga de liberação retardada
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP6770775B2 (ja) 2015-10-16 2020-10-21 アッヴィ・インコーポレイテッド （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
JP2020510016A (ja) 2017-03-09 2020-04-02 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10524489B2 (en) * 2017-07-12 2020-01-07 Zinpro Corporation Method and composition to control rumen release of cobalt to rumen bacteria for making vitamin B12
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
KR20200125637A (ko) 2018-02-23 2020-11-04 크레스토보 홀딩스 엘엘씨 마이크로바이옴 관련 면역요법
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021521177A (ja) * 2018-04-12 2021-08-26 ビーピーエスアイ ホールディングス， エルエルシー 酸性化コーティング及びそれによってコーティングされた崩壊耐性基材
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662902B1 (en) 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
CN113993509A (zh) 2019-05-15 2022-01-28 赢创运营有限公司 用胶囊填充机制备具有基于(甲基)丙烯酸酯共聚物的包衣的填充硬壳胶囊的方法
MX2022000756A (es) 2019-07-19 2022-03-11 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales.
EP4021183A4 (en) * 2019-08-30 2023-05-31 Dow Global Technologies LLC POLAR POLYOLEFIN DISPERSION SEED COATING COMPOSITION
CA3154308A1 (en) 2019-09-13 2021-03-18 Mark Smith Compositions and methods for treating autism spectrum disorder
CN115279382A (zh) 2019-10-18 2022-11-01 芬奇治疗控股有限责任公司 用于向受试者递送细菌代谢物的组合物和方法
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
PL4072532T3 (pl) 2019-12-11 2024-06-10 Evonik Operations Gmbh Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
US20230000780A1 (en) 2019-12-11 2023-01-05 Evonik Operations Gmbh Dosage form comprising an alkaline agent and an enteric coating layer
US20230048354A1 (en) 2019-12-11 2023-02-16 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021202806A1 (en) 2020-03-31 2021-10-07 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
WO2022178294A1 (en) 2021-02-19 2022-08-25 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58135807A (ja) * 1982-02-05 1983-08-12 Shin Etsu Chem Co Ltd 腸溶性被覆薬剤の製造方法
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
HU229291B1 (en) * 2001-01-31 2013-10-28 Evonik Roehm Gmbh Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
KR20040011549A (ko) * 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
CA2444814C (en) * 2001-10-24 2009-06-09 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
MXPA04004747A (es) 2001-11-23 2004-08-02 Procter & Gamble Forma de dosificacion farmaceutica con multiples recubrimientos.
US20060183186A1 (en) * 2001-12-21 2006-08-17 Koh Sang S Gene expression profiles in stomach cancer
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
BR0312876A (pt) * 2002-07-25 2005-06-28 Pharmacia Corp Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
CA2533577C (en) * 2003-07-24 2014-10-21 Smithkline Beecham Corporation Orally dissolving films
JP4277904B2 (ja) 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
US20090110727A1 (en) * 2004-10-12 2009-04-30 Eisai R & D Management Co., Ltd. Extended release compositions of proton pump inhibitors
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
CN101484147B (zh) 2006-08-18 2015-07-08 赢创罗姆有限责任公司 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物
US9237760B2 (en) 2008-01-10 2016-01-19 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon

Also Published As

Publication number Publication date
SI2152250T1 (sl) 2020-06-30
US20130058986A1 (en) 2013-03-07
KR20100016306A (ko) 2010-02-12
CA2687130A1 (en) 2008-11-13
AU2007352872B2 (en) 2013-03-14
DK2152250T3 (da) 2019-12-09
IL201557A (en) 2017-06-29
EP2152250B1 (en) 2019-09-04
AU2007352872A1 (en) 2008-11-13
BRPI0721654B1 (pt) 2019-10-22
JP5167345B2 (ja) 2013-03-21
CN101663027B (zh) 2013-02-27
US9597293B2 (en) 2017-03-21
WO2008135090A8 (en) 2009-03-05
CY1122582T1 (el) 2021-01-27
PT2152250T (pt) 2019-12-12
CA2687130C (en) 2017-10-03
MX2009012030A (es) 2010-01-25
LT2152250T (lt) 2019-12-27
IL201557A0 (en) 2010-05-31
HUE046488T2 (hu) 2020-03-30
WO2008135090A1 (en) 2008-11-13
ES2759626T3 (es) 2020-05-11
BRPI0721654B8 (pt) 2022-07-05
KR101443943B1 (ko) 2014-10-07
BRPI0721654A2 (pt) 2013-01-29
US20100129446A1 (en) 2010-05-27
EP2152250A1 (en) 2010-02-17
US10537530B2 (en) 2020-01-21
JP2010526110A (ja) 2010-07-29
CN101663027A (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
IL201557A0 (en) Solid dosage forms comprising an enteric coating with accelerated drug release
HK1216232A1 (zh) 控釋藥物組合物
PT2073860E (pt) Revestimentos para libertação de fármaco para dispositivos médicos
ZA201005015B (en) Solid pharmaceutical dosage form
GB0703507D0 (en) Solid pharmaceutical dose
IL207128A0 (en) Pharmaceutical dosage form
EP2019665A4 (en) DRUG DISPERSION OF CAPSULES COVERED WITH NANOTEILS
IL201008A0 (en) Modified release dosage forms of tacrolimus
IL207378A0 (en) Pharmaceutical solid state forms
HK1162936A1 (en) Solid pharmaceutical formulation with delayed release
ZA200903858B (en) Pharmaceutical dosage form
EP2172200A4 (en) COATED PREPARATION
EP2217218A4 (en) ENHANCED TABLET COATING
PL2508206T3 (pl) Środek powlekający do preparatu stałego i stały preparat zawierający ten środek
GB0803054D0 (en) Medicament
EP2306944A4 (en) CONDOM WITH CAPSULAR COATING
EP2309854A4 (en) ACCELERATED THERAPY:
EP2227227A4 (en) APPROPRIATE COATING FOR CONTACT WITH A MEDICINAL PRODUCT
IL205492A0 (en) Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
ZA201104564B (en) Low dosage controlled release tablet
EP2241311A4 (en) PHARMACEUTICAL PREPARATION WITH PROGRAMMED RELEASE
GB0717450D0 (en) Medicament
EP2224956A4 (en) THERAPEUTIC TARGETS AND MEDICINES INVOLVING P230 / GOLGINE-245
GB0803395D0 (en) Medicament
GB0723310D0 (en) Solid dosage vaccine